Clearside Biomedical, Inc. (NASDAQ:CLSD) Q1 2024 Earnings Call Transcript

Victor Chong: Yes. I think that when the guideline are more than a year old and it is still not finalized. And obviously that the community has some potential concern, but yes, that is not unusual for FDA to have a draft guideline for a long time as well. So it’s hard to predict, but that suggested that some of the point on the guidelines was inconsistent with practice. So again, that is — those are the something that I think everyone are discussing in multiple different conferences in the multiple different platforms. But again, exactly when that guide — that draft guideline will become finalized or even — or moving to interim is still difficult to be sure. And especially, as you know, that there’s a recent leadership change in FDA as well that whether there might be late things as well.

George Lasezkay: And obviously, as we go forward before we announce any Phase 3 plans, we will have been engaged at least once, if not multiple times with the agency to discuss Phase 3 trial design. So we’ll get the most up-to-date reading from the agency in our conversations with them as our planning continues.

Unidentified Analyst: Got it. Thank you. Thanks again for your thoughtful answers.

George Lasezkay: Okay.

Operator: I would now like to turn the call back to George Lasezkay for any further remarks.

George Lasezkay: Well, I want to thank everybody for being on the call today. We look forward to keeping you apprised of our progress. And with that, I would say that the operator, you can end the call.

Operator: This concludes today’s Clearside Biomedical first quarter 2024 financial results and corporate update call. Thank you for attending, and have a wonderful rest of your day.